Summary
This article provides an overview of the role of lung ultrasound (LUS) in assessing interstitial lung disease (ILD) in systemic sclerosis (SSc) and discusses the current state of validation supporting its clinical relevance and application in daily clinical practice.
A systematic review was conducted, including original articles published between January 1997 and October 2017. Twelve articles were analyzed out of 300 identified papers. The review found that LUS demonstrated face, content validity, and feasibility; however, there is insufficient evidence to support criterion validity, reliability, and sensitivity to change.
Despite considerable potential, more work is needed to validate the use of LUS as an outcome measure in ILD associated with systemic sclerosis.
